Onco-Innovations Advances ONC010 Manufacturing Development With Nanosoft

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced a significant advancement in the development of its lead drug candidate, ONC010, by initiating polymer process development and analytical characterization activities with Nanosoft Polymers. This collaboration is a key component of the company's chemistry, manufacturing, and controls (CMC) strategy aimed at establishing a scalable, reproducible, and analytically characterized polymer platform to support future formulation, manufacturing, regulatory, and clinical development.

ONC010 is a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor, a novel approach targeting solid tumors. The activities undertaken by Nanosoft include polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement, and manufacturing scalability assessments. These efforts are designed to ensure that the polymer platform can be produced consistently and at a scale suitable for Good Manufacturing Practice (GMP) production, which is essential for clinical trials and eventual commercialization.

Onco-Innovations highlighted that Nanosoft's expertise in polymer science and nanoparticle drug delivery will strengthen the technical foundation of the ONC010 platform. The company expects that this partnership will accelerate the path toward regulatory submissions and clinical trials by providing robust data on the manufacturing process and product quality.

This development is important for Onco-Innovations as it moves beyond early-stage research into the practical challenges of drug manufacturing. The ability to produce ONC010 consistently and at scale is a prerequisite for regulatory approval and patient access. By addressing these manufacturing hurdles now, Onco-Innovations is positioning itself to avoid common delays in drug development and to potentially bring a novel cancer therapy to market more efficiently.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. This partnership with Nanosoft represents a strategic investment in the technical infrastructure needed to advance its pipeline.

For more information on Onco-Innovations and its latest news, visit the company's newsroom at https://nnw.fm/ONNVF. The full press release regarding this announcement is available at https://nnw.fm/BeSoS.